A recent report by the World Health Organization (WHO) reveals that India has significantly contributed to global genomic research, featuring in 235 genomic studies conducted over a 34-year period, specifically between 1990 and 2024. This makes India the most active lower-middle-income country in global genomic clinical research. The WHO's analysis, which reviewed over 6,500 clinical studies globally that utilize human genomic technologies, highlights a pronounced imbalance in research distribution. Over 80% of these studies are concentrated in high-income countries, while low and middle-income countries (LMICs) collectively account for less than 5% of all registered genomic studies. The report, titled 'Human genomics technologies in clinical studies-the research landscape,' points out that India's prominent presence is largely due to its inclusion as a study site in multi-country trials rather than locally led genomic programs. Furthermore, there's a significant bias in research focus; more than 75% of genomic studies globally concentrate on non-communicable diseases (NCDs) such as cancer, rare diseases, and metabolic disorders. In stark contrast, communicable diseases like tuberculosis, HIV, and malaria, which pose a heavy burden in countries like India, account for only 3-5% of genomic studies. The WHO terms this a 'missed opportunity' to apply genomic insights to infectious diseases. To address this 'genomic divide,' the report advocates for global coordination, increased investment in genomic infrastructure within underrepresented settings, inclusive research designs aligned with diverse public health needs, and capacity building to support LMIC-led research.